BPRG Bioprogress

RNS Number:4691X
BioProgress PLC
31 May 2007


For Immediate Release                                               31 May 2007

                BioProgress plc ('BioProgress' or the 'Company')

                     Total Voting Rights and Share Capital



London, UK, 31 May 2007: BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty
pharma and healthcare company is required to notify the market of the following:



BioProgress' issued share capital consists of 167,759,591 ordinary shares with a
nominal value of 1 pence each, with voting rights. BioProgress does not hold any
ordinary shares in Treasury.



Therefore, the total number of voting rights in BioProgress is 167,759,591.



The above figure of 167,759,591 shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
BioProgress under the Financial Service Authority's Disclosure and Transparency
Rules.





For further information:


BioProgress Plc                                    + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                            + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL(TM) polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com



Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TVRILFIDEFIIVID

Bioprogress (LSE:BPRG)
Historical Stock Chart
From Oct 2024 to Nov 2024

Bioprogress (LSE:BPRG)
Historical Stock Chart
From Nov 2023 to Nov 2024